Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
Phase IIA, Single-Arm, Open- Label, Clinical Trial of Calcipotriene Plus 5-fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients
Sponsor: National Cancer Institute (NCI)
Listed as NCT05699603, this PHASE2 trial focuses on Actinic Keratosis and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 17 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
▶ Show 12 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE2
-
May 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Arizona
For direct contact, visit the study record on ClinicalTrials.gov .